NovoCure’s (NVCR) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reissued their buy rating on shares of NovoCure (NASDAQ:NVCR – Free Report) in a research report released on Thursday,Benzinga reports. They currently have a $30.00 price objective on the medical equipment provider’s stock. Several other research firms have also recently weighed in on NVCR. Wedbush reaffirmed an “outperform” rating and issued a $24.00 […]
More Stories
One Hundred Years of Solitude Season 2: Release Date, Cast Members, Trailer, and More
The best-selling novel One Hundred Years of Solitude by Nobel Prize-winning Colombian author García Márquez is coming back as a...
When Your Payment Provider Can No Longer Keep Up
A payment account can work perfectly well until the business starts growing. Sales rise and customers arrive from new countries,...
The Hawk Season 2 Updates: Where Did Season 1 End
Netflix’s 2026 series, The Hawk, has been released. It has received a mixed response from the audience in different parts...
Netflix’s Upcoming Sports Documentary: Mourinho Is Releasing Soon
Football fans, be ready! Netflix is about to drop one of its most-awaited sports documentaries of 2026. Mourinho is a...
Order of the Sinking Star is Ready to Launch on PlayStation 5 and TV
The creator of Braid and The Witness, Jonathan Blow, is returning with an all-new puzzle video game, Order of the...
Netflix’s Upcoming Drama, All the Truth in My Lies: Release Date, Cast, and More
Excited to know about the upcoming Spanish drama on Netflix, All the Truth in My Lies. If you love watching...